Protection against infection with the Omicron BA.5 subvariant among people with previous SARS-CoV-2 infection - surveillance results from southern Sweden, June to August 2022
Kahn, F.; Bonander, C.; Moghaddassi, M.; Bennet, L.; Malmqvist, U.; Inghammar, M.; Bjork, J.
Show abstract
We evaluated the protection afforded by SARS-CoV-2 natural infection against reinfection among vaccinated during a calendar period from June to August 2022 when Omicron BA.5 was the dominating subvariant in Scania county, Sweden. We formed a study cohort (n = 71 592) mainly consisting of health care workers by restricting to people 18-64 years old who received their first vaccine dose relatively early (24 April 2021 or sooner). We used continuous density case-control 1:10 sampling matched for sex and age within the study cohort, and thereby obtained 1 114 cases during Omicron BA.5 dominance and 11 140 controls who were analysed with conditional logistic regression. Limited protection against reinfection was suggested from prior infection of virus variants before Omicron (11%, 95% confidence interval [CI] -10 to 28%]. By contrast, prior Omicron infection offered clear protection (65%, 95% CI 56-73%). For the Omicron BA.2 subvariant, stronger protection was suggested during early (85%, 95% CI 75-91%) than later BA.5 dominance (66%, 95% CI 48-78%). Lower protection was observed from the previous BA.1 subvariant (30%; 95% CI -4 to 53%). These findings suggest that natural infection from the Omicron subvariants contributes to short-term population protection against reinfection with the subvariant BA.5 among vaccinated, but wanes considerably 5-6 months after infection.
Matching journals
The top 8 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Protection of COVID-19 vaccination and previous infection against Omicron BA.1 and Delta SARS-CoV-2 infections, the Netherlands, 22 November 2021- 19 January 2022 95%
- Effect of booster vaccination against Delta and Omicron variants in Iceland 94%
- Effectiveness of ChAdOx1-S COVID-19 Booster Vaccination against the Omicron and Delta variants in England 94%
Similar papers in this journal
- Risk of severe COVID-19 from the Delta and Omicron variants in relation to vaccination status, sex, age and comorbidities – surveillance results from southern Sweden 96%
- Higher risk of SARS-CoV-2 Omicron BA.4/5 infection than of BA.2 infection after previous BA.1 infection, the Netherlands, 2 May to 24 July 2022 96%
- SARS-CoV-2 infection in households with and without young children: Nationwide cohort study 93%
Similar papers in this journal
- Comparative effectiveness of different primary vaccination courses on mRNA based booster vaccines against SARs-COV-2 infections: A time-varying cohort analysis using trial emulation in the Virus Watch community cohort 93%
- Cohort profile: Virus Watch: Understanding community incidence, symptom profiles, and transmission of COVID-19 in relation to population movement and behaviour 91%
- The effect of SARS-CoV-2 testing on healthcare seeking behaviour at primary care level: implications for COVID-19 vaccine effectiveness estimates in test-negative design studies. 90%
Similar papers in this journal
- Effectiveness of BNT162b2 mRNA vaccine third doses and previous infection in protecting against SARS-CoV-2 infections during the Delta and Omicron variant waves; the UK SIREN cohort study September 2021 to February 2022 94%
- Protection of vaccine boosters and prior infection against mild/asymptomatic and moderate COVID-19 infection in the UK SIREN healthcare worker cohort: October 2023 to March 2024 93%
- Trajectories of hospitalisation for patients infected with SARS-CoV-2 variant B.1.1.7 in Norway, December 2020 – April 2021 93%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.